Fig. 5

Silencing LINC00665 or overexpressing miR-582-5p enhanced the sensitivity of NSCLC cells to radiotherapy. A, Cell viability in A549 cells treated with sh-LINC00665 or miR-582-5p mimic or in PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor determined by CCK-8 assay. B, Colony formation potential of A549 treated with sh-LINC00665 or miR-582-5p mimic or of PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor determined by colony formation assay. C, Cell invasion in A549 cells treated with sh-LINC00665 or miR-582-5p mimic or in PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor determined by Transwell assay. D, Detection of γH2ax fluorescence in A549 cells treated with sh-LINC00665 or miR-582-5p mimic or in PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor. E, Flow cytometry analysis of cell apoptosis in A549 cells treated with sh-LINC00665 or miR-582-5p mimic or in PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor. F, Flow cytometry analysis of cell cycle distribution in A549 cells treated with sh-LINC00665 or miR-582-5p mimic or in PC9 cells treated with LV-LINC00665 or miR-582-5p inhibitor. * p < 0.05 versus the A549 cells treated with sh-NC or mimic NC; # p < 0.05 versus the PC9 cells treated with Vector or inhibitor NC. Each cellular experiment was repeated 3 times